Technical Analysis for KRON - Kronos Bio, Inc.

Grade Last Price % Change Price Change
F 23.2894 -8.35% -2.12
KRON closed down 6.85 percent on Monday, April 12, 2021, on 2.26 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical KRON trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish -8.35%
Lower Bollinger Band Walk Weakness -8.35%
New 52 Week Low Weakness -8.35%
Stochastic Reached Oversold Weakness -8.35%
Below Lower BB Weakness -8.35%
Lower Bollinger Band Touch Weakness -8.35%
Oversold Stochastic Weakness -8.35%
NR7 Range Contraction -14.63%
Lower Bollinger Band Walk Weakness -14.63%
Inside Day Range Contraction -14.63%
Older End-of-Day Signals for KRON ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 10% about 2 hours ago
1.5x Volume Pace about 3 hours ago
Down 1 ATR about 3 hours ago
60 Minute Opening Range Breakdown about 3 hours ago
Down 5% about 3 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Classification

Sector: Other
Industry: Other
Keywords: Biopharmaceutical Biology Solid Tumors Acute Myeloid Leukemia Enzymes Tyrosine Kinase Transcription Cancer Therapeutics Novel Cancer Transcription Factors Transcription Factor Cyclin Dependent Kinase Entospletinib Kronos Morpholines

Is KRON a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 39.6
52 Week Low 25.3
Average Volume 203,536
200-Day Moving Average 0.00
50-Day Moving Average 28.58
20-Day Moving Average 28.31
10-Day Moving Average 27.95
Average True Range 1.83
ADX 13.16
+DI 14.90
-DI 23.34
Chandelier Exit (Long, 3 ATRs ) 26.68
Chandelier Exit (Short, 3 ATRs ) 30.80
Upper Bollinger Band 30.09
Lower Bollinger Band 26.53
Percent B (%b) -0.32
BandWidth 12.56
MACD Line -0.51
MACD Signal Line -0.24
MACD Histogram -0.2642
Fundamentals Value
Market Cap 1.42 Billion
Num Shares 56 Million
EPS
Price-to-Sales 0.00
Price-to-Book 23.24
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.28
Resistance 3 (R3) 28.56 27.88 27.80
Resistance 2 (R2) 27.88 27.15 27.74 27.64
Resistance 1 (R1) 26.65 26.70 26.31 26.37 27.48
Pivot Point 25.97 25.97 25.81 25.83 25.97
Support 1 (S1) 24.74 25.24 24.40 24.46 23.34
Support 2 (S2) 24.06 24.79 23.92 23.18
Support 3 (S3) 22.83 24.06 23.02
Support 4 (S4) 22.55